Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Neurology

Treatment Strategy: The Path to Stability

At a Glance

The primary treatment for Cerebrotendinous Xanthomatosis (CTX) is lifelong daily therapy with chenodeoxycholic acid (CDCA). This medication stops the toxic buildup of cholestanol in the body. Treatment must never be interrupted, as stopping can cause rapid, irreversible neurological decline.

The management of Cerebrotendinous Xanthomatosis (CTX) has a very clear objective: stop the toxic buildup of cholestanol by fixing the “broken” metabolic pathway [1]. Because CTX is a progressive condition, the treatment strategy is lifelong and requires strict adherence to ensure the brain and nervous system remain protected [2][3].

The Standard of Care: Chenodeoxycholic Acid (CDCA)

The primary and most effective treatment for CTX is chenodeoxycholic acid (CDCA) [4]. As discussed in the biology of the disease, the bodies of people with CTX cannot produce enough of this natural bile acid [1].

CDCA works through a mechanism called feedback inhibition:

  • The Replacement: By taking CDCA as a medication, you are providing your body with the bile acid it is missing [5].
  • The Off-Switch: When the body senses it has enough CDCA, it sends a signal to the “assembly line” to stop production. This shuts down the “toxic shortcut” that was creating cholestanol and bile alcohols [1][6].
  • The Result: Over time, blood levels of cholestanol drop significantly, which helps stop further damage to the brain, nerves, and tendons [2][7].

Daily Logistics and Side Effects: CDCA is typically taken as an oral capsule, often divided into multiple doses taken with meals. While highly effective, CDCA can cause dose-dependent diarrhea and carries a risk of hepatotoxicity (liver damage) [8]. Therefore, routine monitoring of your liver enzymes is a mandatory part of your ongoing care [9].

The Power of Early Intervention

The timing of treatment is the single most important factor in a patient’s long-term outlook.

  • Preventing Damage: When CDCA is started early—ideally before major neurological symptoms appear—it can completely arrest the progression of the disease [10][11].
  • Reversing Symptoms: In some cases, early treatment can even reverse existing issues, such as childhood diarrhea or certain behavioral changes [2][3].
  • Managing Established Symptoms: For late-diagnosed patients where significant damage to the brain’s structure or the spinal cord has already occurred (often seen as “white matter” changes on an MRI), some symptoms may be irreversible [12][13]. In these cases, treatment is still absolutely critical—the goal shifts to preventing any further decline and maintaining your current quality of life [14].
  • The Timeline: Once treatment begins, blood cholestanol levels typically start to drop within weeks to a few months, providing an early, measurable milestone of success [15].

A Critical Warning: Never Interrupt Therapy

Stopping CDCA therapy, even for a short time, is considered dangerous [15].

  • Rapid Spikes: Without the “off-switch” provided by the medication, the body immediately begins overproducing toxic metabolites again [15][13].
  • Neurological Decline: Research shows that even brief interruptions can lead to a sudden and sometimes irreversible decline in neurological function and mental health [16][17]. Consistency is the most vital part of managing CTX.

Alternatives and Adjunctive Therapies

While CDCA is the gold standard, other options exist to help tailor treatment to each patient.

Cholic Acid (CA)

For patients who cannot tolerate CDCA due to side effects like diarrhea or liver irritation, Cholic Acid (CA) is an effective alternative [18]. It works similarly to CDCA by replacing missing bile acids and has been shown to stabilize symptoms and lower cholestanol in the majority of patients [18][19].

Statins

Statins (HMG-CoA reductase inhibitors), commonly used for high cholesterol, are sometimes used as an “add-on” (adjunctive) therapy alongside CDCA [20]. They help by blocking the body’s ability to create the building blocks of cholesterol, which can further lower the amount of cholestanol in the blood [20]. However, statins should never be used instead of bile acid replacement therapy.

Common questions in this guide

How does CDCA treat Cerebrotendinous Xanthomatosis?
Chenodeoxycholic acid (CDCA) replaces the missing bile acid your body needs. This signals your body to stop producing toxic cholestanol, which helps prevent further damage to your brain, nerves, and tendons.
Can CTX symptoms be reversed with treatment?
If treatment begins early, it can arrest the progression of the disease and sometimes reverse symptoms like childhood diarrhea or behavioral changes. However, significant structural damage to the brain or spinal cord may be irreversible, so the goal shifts to preventing further decline.
What happens if I miss a dose or stop taking my CTX medication?
Stopping CDCA therapy is dangerous because your body immediately begins overproducing toxic metabolites again. Even brief interruptions can lead to a sudden and sometimes irreversible decline in neurological function.
What are the side effects of CDCA therapy?
CDCA can cause dose-dependent diarrhea and carries a risk of liver damage. Routine monitoring of your liver enzymes is required to ensure the medication is safe and effective for you.
What if I cannot tolerate CDCA medication?
If you experience severe side effects or liver irritation from CDCA, your doctor may prescribe Cholic Acid (CA) as an alternative. It works similarly to replace missing bile acids and has been shown to stabilize symptoms.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is the target serum cholestanol level for me (or my child), and how often will we test it to ensure the dose is correct?
  2. 2.If we experience any side effects from CDCA, what is the process for transitioning to Cholic Acid?
  3. 3.Are the current neurological symptoms we see considered reversible, or is the goal now to prevent further decline?
  4. 4.Should we consider adding a statin to the CDCA regimen to further lower cholestanol levels?
  5. 5.What is the backup plan if there is ever an insurance delay or supply issue with CDCA, given the risks of interrupting therapy?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (20)
  1. 1

    A Preventable Ataxia: Cerebrotendinous Xanthomatosis.

    Shaji B, Srikumar B, Ramachandran D

    Annals of Indian Academy of Neurology 2019; (22(4)):493-496 doi:10.4103/aian.AIAN_126_18.

    PMID: 31736580
  2. 2

    The safety and effectiveness of chenodeoxycholic acid treatment in patients with cerebrotendinous xanthomatosis: two retrospective cohort studies.

    Verrips A, Dotti MT, Mignarri A, et al.

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2020; (41(4)):943-949 doi:10.1007/s10072-019-04169-8.

    PMID: 31863326
  3. 3

    Patients with Lately Diagnosed Cerebrotendinous Xanthomatosis.

    Yunisova G, Tufekcioglu Z, Dogu O, et al.

    Neuro-degenerative diseases 2019; (19(5-6)):218-224 doi:10.1159/000506770.

    PMID: 32349000
  4. 4

    FDA Approves First Targeted Treatment for Cerebrotendinous Xanthomatosis: A Perspective on a Landmark in Rare Lipid Storage Disease Therapy.

    Jalal L, Basaria AAA, Yokolo H

    Health science reports 2025; (8(12)):e71549 doi:10.1002/hsr2.71549.

    PMID: 41324091
  5. 5

    Pathophysiology and Treatment of Lipid Abnormalities in Cerebrotendinous Xanthomatosis: An Integrative Review.

    Ribeiro RM, Vasconcelos SC, Lima PLGSB, et al.

    Brain sciences 2023; (13(7)) doi:10.3390/brainsci13070979.

    PMID: 37508912
  6. 6

    Expanding the clinical spectrum of cerebrotendinous xanthomatosis: Implications for newborn screening, follow-up and treatment.

    Hollak CEM

    Journal of internal medicine 2021; (290(5)):942-943 doi:10.1111/joim.13276.

    PMID: 33760321
  7. 7

    Brain diffusion tensor imaging changes in cerebrotendinous xanthomatosis reversed with treatment.

    Catarino CB, Vollmar C, Küpper C, et al.

    Journal of neurology 2018; (265(2)):388-393 doi:10.1007/s00415-017-8711-9.

    PMID: 29260356
  8. 8

    Hepatotoxicity due to chenodeoxycholic acid supplementation in an infant with cerebrotendinous xanthomatosis: implications for treatment.

    Huidekoper HH, Vaz FM, Verrips A, Bosch AM

    European journal of pediatrics 2016; (175(1)):143-6 doi:10.1007/s00431-015-2584-7.

    PMID: 26156051
  9. 9

    Sterol 27-Hydroxylase Deficiency as a Cause of Neonatal Cholestasis: Report of 2 Cases and Review of the Literature.

    Lipiński P, Klaudel-Dreszler M, Ciara E, et al.

    Frontiers in pediatrics 2020; (8()):616582 doi:10.3389/fped.2020.616582.

    PMID: 33520900
  10. 10

    Cerebrotendinous xanthomatosis: A rare neurodegenerative disorder with characteristic imaging findings.

    Khan HG, Raj G, Yadav E, et al.

    Radiology case reports 2025; (20(9)):4347-4351 doi:10.1016/j.radcr.2025.05.040.

    PMID: 40583979
  11. 11

    A Novel Compound Heterozygous CYP27A1 Variant in Cerebrotendinous Xanthomatosis: A Case Report from a Non-Consanguineous Family.

    Cesur Baltacı HN, Sağlam Ada B, Yürür Kutlay N, et al.

    Molecular syndromology 2026; (17(2)):160-168 doi:10.1159/000547016.

    PMID: 41064050
  12. 12

    Cerebrotendinous Xanthomatosis: Molecular Pathogenesis, Clinical Spectrum, Diagnosis, and Disease-Modifying Treatments.

    Koyama S, Sekijima Y, Ogura M, et al.

    Journal of atherosclerosis and thrombosis 2021; (28(9)):905-925 doi:10.5551/jat.RV17055.

    PMID: 33967188
  13. 13

    Spinal cerebrotendinous xanthomatosis: A case report and literature review.

    Atallah I, Millán DS, Benoît W, et al.

    Molecular genetics and metabolism reports 2021; (26()):100719 doi:10.1016/j.ymgmr.2021.100719.

    PMID: 33659184
  14. 14

    Metabolic profiling in serum, cerebrospinal fluid, and brain of patients with cerebrotendinous xanthomatosis.

    Höflinger P, Hauser S, Yutuc E, et al.

    Journal of lipid research 2021; (62()):100078 doi:10.1016/j.jlr.2021.100078.

    PMID: 33891937
  15. 15

    Efficacy, safety, and tolerability of chenodeoxycholic acid (CDCA) in adult patients with cerebrotendinous xanthomatosis (RESTORE): A randomized withdrawal, double-blind, placebo-controlled, crossover phase-3 study.

    Kisanuki YY, Nobrega PR, Himes R, et al.

    Genetics in medicine : official journal of the American College of Medical Genetics 2025; (27(7)):101449 doi:10.1016/j.gim.2025.101449.

    PMID: 40297984
  16. 16

    Patents vs patients 1-0: The case of chenodeoxycholic acid.

    Briké SM, Meersseman W, Cassiman D

    Journal of inherited metabolic disease 2022; (45(2)):377-378 doi:10.1002/jimd.12443.

    PMID: 34599614
  17. 17

    Using fiber tractography and diffusion kurtosis imaging to evaluate neuroimaging changes in patients with cerebrotendinous xanthomatosis after stopping chenodeoxycholic acid treatment for three years.

    Lee JJ, Chang CC, Chang WN

    Biomedical journal 2022; (45(5)):814-820 doi:10.1016/j.bj.2021.09.003.

    PMID: 34543727
  18. 18

    Cholic acid as a treatment for cerebrotendinous xanthomatosis in adults.

    Mandia D, Chaussenot A, Besson G, et al.

    Journal of neurology 2019; (266(8)):2043-2050 doi:10.1007/s00415-019-09377-y.

    PMID: 31115677
  19. 19

    Cholic acid as a treatment for cerebrotendinous xanthomatosis: a comprehensive review of safety and efficacy.

    Pasternack G, Courtney J, Kalsi G

    Orphanet journal of rare diseases 2025; (20(1)):387 doi:10.1186/s13023-025-03889-9.

    PMID: 40731019
  20. 20

    Nationwide survey on cerebrotendinous xanthomatosis in Japan.

    Sekijima Y, Koyama S, Yoshinaga T, et al.

    Journal of human genetics 2018; (63(3)):271-280 doi:10.1038/s10038-017-0389-4.

    PMID: 29321515

This page provides general educational information about treatment strategies for Cerebrotendinous Xanthomatosis (CTX). Always consult your healthcare provider or metabolic specialist before starting, adjusting, or stopping any medication.

Get notified when new evidence is published on Cerebrotendinous xanthomatosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.